<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="85693">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01942850</url>
  </required_header>
  <id_info>
    <org_study_id>ICARS-CGI-Ery01-2013</org_study_id>
    <nct_id>NCT01942850</nct_id>
  </id_info>
  <brief_title>International Ataxia Rating Scale in Younger Patients</brief_title>
  <official_title>APPLICABILITY OF THE INTERNATIONAL ATAXIA RATING SCALE (ICARS) IN YOUNGER PATIENTS AND DEVELOPMENT OF GLOBAL RATING INSTRUMENTS FOR PATIENTS WITH ATAXIA TELANGIECTASIA (AT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erydel</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Erydel</source>
  <oversight_info>
    <authority>Italy: Ethics Committee</authority>
    <authority>Israel: Ethics Commission</authority>
    <authority>India: Institutional Review Board</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The project will collect information on the mapping of clinical ratings on a number of
      scales that are used in the assessment of patients with ataxias.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">March 2014</completion_date>
  <primary_completion_date type="Anticipated">February 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Correlation Analysis</measure>
    <time_frame>single visit</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary outcome is validity of ICARS in children younger than 10 years of age (by comparing the mean scores and subscores between children aged 6-10 years of age to those aged 10-18 years of age).</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Ataxia Telangiectasia</condition>
  <arm_group>
    <arm_group_label>No Treatment</arm_group_label>
    <description>Collect pilot data on the performance of the ICARS in patients younger than 10 years of age, as well as to introduce definitions for the various clinically defined stages of AT, and attempt to develop descriptors of change that could help in the assessment of patients longitudinally.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Known patients with ataxia/ataxia telangiectasia
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria

          1. Patients aged 6-18 years with diagnosed with ataxia, preferably AT will be included.
             The diagnosis of AT will be made based on the criteria: typical clinical picture plus
             one of the following: 1. a proven mutation in the ATM gene 2. Deficient ATM protein
             proven by Western blotting 3. Elevated Î±-fetoprotein, cerebellar atrophy on MRI and
             immune deficiency/ chromosomal breakage/ T- cell lymphoreticular malignancy.

          2. Children aged 6-18 years with suspected AT (fulfilling partially the above criteria
             will be included)

          3. Children aged 6-18 years with AT like disease, with or without proven mutation in the
             MRE11 gene will be included

          4. Children aged 6-18 years of age with ataxia of other known or unknown etiologies
             might be included, but their total number should not exceed 20% of the cohort in each
             site
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luca Benatti, MD</last_name>
    <role>Study Director</role>
    <affiliation>Erydel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Luca Benatti, MD</last_name>
    <email>luca.benatti@erydel.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marian Sidlowski</last_name>
    <email>msidlowski@clinirx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Carol Morsani USF Health Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theresa A Zesiewicz, MD FAAN</last_name>
      <phone>813-974-5909</phone>
      <email>tzesiewi@health.usf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kelly Sullivan, PhD</last_name>
      <phone>(813) 974-5909</phone>
      <email>kbarber@health.usf.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Theresa A Zesiewicz, MD FAAN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jaslok Hospital</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anaaita Hedge</last_name>
    </contact>
    <investigator>
      <last_name>Anaaita Hedge, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Edmond and Lilly Safra Childrens Hospital Pediatric Unit</name>
      <address>
        <city>Tel Hashomer</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreea Nissenkorn, MD</last_name>
      <phone>972-3530-5061</phone>
      <email>andreea.nissenkorn@sheba.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Andreea Nissenkorn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O Spedalli Civilli Brescia</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Micheli, MD</last_name>
      <phone>39-030-3995721</phone>
      <email>micheli.roby@tin.it</email>
    </contact>
    <investigator>
      <last_name>Roberto Micheli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>India</country>
    <country>Israel</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 17, 2014</lastchanged_date>
  <firstreceived_date>September 6, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ataxia</mesh_term>
    <mesh_term>Ataxia Telangiectasia</mesh_term>
    <mesh_term>Telangiectasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
